EQS-News

SG-based Startup Galatek Raises $30M Series A to Accelerate AI-powered Automation in Life Sciences and Semiconductor Manufacturing 19.12.2025, 03:50 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Galatek / Key word(s): Private Equity
SG-based Startup Galatek Raises $30M Series A to Accelerate AI-powered Automation in Life Sciences and Semiconductor Manufacturing

19.12.2025 / 03:50 CET/CEST
The issuer is solely responsible for the content of this announcement.


SINGAPORE, Dec. 19, 2025 /PRNewswire/ -- Galatek, a fast-growing Singapore-based automation and artificial intelligence (AI) startup, announced today that it has secured approximately US$30 million in Series A funding. The funding will accelerate the company's development of innovative products in life sciences and advanced semiconductor manufacturing, strengthen its global supply chain, and deepen local expertise in key markets across Europe, North America, and Southeast Asia.

As AI continues to accelerate digital transformation across industries, Galatek addresses critical challenges in life sciences and semiconductor manufacturing. The company provides automation and AI solutions that are reshaping smart labs and advanced packaging - key sectors where precision and intelligence define the next generation of innovation. Based in Singapore's innovation hub, Galatek combines its agile, globally-connected R&D with localized commercial presence in strategic markets, positioning itself as an essential enabler of industrial progress in the AI era.

Galatek is strategically focused on two high-demand market areas where significant technology gaps remain:

In Life Sciences

The company is pioneering the smart laboratory of the future. By deeply integrating AI into R&D and service workflows, Galatek empowers scientists to accelerate and de-risk discovery across complex applications, including diagnostics, NGS sequencing, 3D cell & organoid culture, drug development, and synthetic biology. This is further enhanced through Galatek's Abio software platform, an integrated AI-driven solution that unifies ELN, LIMS, SDMS and advanced automation to transform scientific data into actionable insights, streamline robotic integrations, and support customizable, cloud-agnostic smart lab operations through its extensible architecture. Galatek has forged strategic partnerships with top-tier global pharmaceutical firms and research institutions and has co-created next-generation smart labs with world-renowned academic partners like the National University of Singapore, building a pipeline for sustained technology leadership.

In Semiconductors

Galatek is also focused on AI-driven innovation and implementation for advanced packaging. With deep integration of vision AI and motion control algorithms, it is meeting extreme demands for precision and reliability. The company provides critical process equipment and solutions ranging from front-end metrology and inspection to back-end advanced packaging. Core solutions include fully automated overlay measurement systems, deep learning-based automatic optical inspection (AOI) systems, and precision wafer dicing equipment. Galatek is currently collaborating with several leading global semiconductor manufacturers, demonstrating end-to-end commercialization capabilities from technology breakthrough to scaled delivery.

Galatek's business model, "Global Supply Chain + Localized Service," combines the competitive advantages of Asian supply chains with company-owned delivery centers in Malaysia and the United States, creating a resilient global logistics network. In key markets, local teams in Europe, North America, and Southeast Asia provide proactive, customized support across the entire customer journey, from sales and technical service to compliance, ensuring clients receive a seamlessly integrated offering.

"The global industry is undergoing a fundamental transformation, driven by artificial intelligence and automation," said David Tian, CEO of Galatek. "The need for smart laboratories in life sciences and the innovation imperative in semiconductor advanced packaging are not just sector-specific needs - these are critical junctures where we are focused. Galatek's mission is to be a reliable infrastructure partner in this transformation. By combining world-class supply chain capabilities with local resources, we are confident in delivering the innovative solutions that global clients need - solutions that are often difficult for traditional providers to deploy rapidly. This Series A funding accelerates our journey to fulfill that role at scale." 

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/sg-based-startup-galatek-raises-30m-series-a-to-accelerate-ai-powered-automation-in-life-sciences-and-semiconductor-manufacturing-302646549.html

rt.gif?NewsItemId=EN50676&Transmission_Id=202512182146PR_NEWS_EURO_ND__EN50676&DateId=20251218


19.12.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2248802  19.12.2025 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 23:02 Uhr • Artikel • dpa

Gestern 22:46 Uhr • Artikel • dpa

Gestern 22:40 Uhr • Artikel • dpa-AFX

Gestern 22:32 Uhr • Artikel • dpa-AFX

Gestern 22:04 Uhr • Artikel • dpa-AFX

Gestern 22:02 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer